Emergent BioSolutions Inc (EBS)
7.49
+0.21
(+2.88%)
USD |
NYSE |
Sep 27, 16:00
7.50
+0.01
(+0.13%)
After-Hours: 20:00
Emergent BioSolutions SG&A Expense (Annual): 368.40M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 368.40M |
| December 31, 2022 | 339.50M |
| December 31, 2021 | 348.70M |
| December 31, 2020 | 304.10M |
| December 31, 2019 | 273.50M |
| December 31, 2018 | 202.50M |
| December 31, 2017 | 142.90M |
| December 31, 2016 | 143.10M |
| December 31, 2015 | 121.14M |
| December 31, 2014 | 108.59M |
| December 31, 2013 | 87.88M |
| Date | Value |
|---|---|
| December 31, 2012 | 76.02M |
| December 31, 2011 | 74.28M |
| December 31, 2010 | 76.20M |
| December 31, 2009 | 73.79M |
| December 31, 2008 | 55.08M |
| December 31, 2007 | 55.56M |
| December 31, 2006 | 44.60M |
| December 31, 2005 | 42.79M |
| December 31, 2004 | 30.32M |
| December 31, 2003 | |
| December 31, 2002 | 13.40M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
273.50M
Minimum
2019
368.40M
Maximum
2023
326.84M
Average
339.50M
Median
2022
SG&A Expense (Annual) Benchmarks
| Geovax Labs Inc | 6.022M |
| Tonix Pharmaceuticals Holding Corp | 34.75M |
| Abbott Laboratories | 10.95B |
| SIGA Technologies Inc | 22.04M |
| Chimerix Inc | 24.60M |